UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 Or 15d-16 Of
The Securities Exchange Act Of 1934
For the month of November 2024
Commission File Number: 001-14950
ULTRAPAR HOLDINGS INC.
(Translation of Registrant’s Name into English)
Brigadeiro Luis Antonio Avenue, 1343, 9th Floor
São Paulo, SP, Brazil 01317-910
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ____X____ Form 40-F ________
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ________ No ____X____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ________ No ____X____
ULTRAPAR PARTICIPAÇÕES S.A.
Publicly Traded Company
CNPJ Nr. 33.256.439/0001-39
|
NIRE 35.300.109.724
|
MINUTES OF THE MEETING OF THE BOARD OF DIRECTORS
Date, Hour and Place:
November 28, 2024, at 17 p.m, at the Company’s headquarters, located at Brigadeiro Luís Antônio Avenue, Nr. 1.343, 9th floor, in the City and State of São Paulo.
Members in attendance:
(i) Members of the Board of Directors undersigned; (ii) Secretary of the Board of Directors, Ms. Denize Sampaio Bicudo; (iii) Chief Executive Officer, Mr. Marcos Marinho Lutz; and (iv) Chief Financial and Investor Relations Officer, Mr. Rodrigo de Almeida Pizzinatto.
Matters discussed and resolutions:
1.The Board of Directors approved, unanimously, as proposed by the Executive Board and in compliance with the provisions of art. 27, item “n” of the Company’s Bylaws and CVM Resolution 77/22 (“RCVM 77/22”), the new Company’s Shares Buyback Program, through which the Company may acquire in the stock exchange, at B3 S.A. – Brasil, Bolsa, Balcão, up to 25,000,000 (twenty-five million) common shares issued by the Company, corresponding, on this date, 2.24% of the capital stock, for use in the Company's stock-based incentive plan, as approved by the extraordinary general meeting held on April 19, 2023, maintenance in treasury and/or subsequent sale or cancellation, without capital reduction ("Program"). This Program will end on December 2, 2025.
2. In addition, it was stated that (i) the objectives, justifications, terms and conditions applicable to the Program are set out in Exhibit I to these minutes, which contains the information required by "Exhibit G" of CVM Resolution 80/22; and (ii) the Program is in line with the terms of the Company's Material Notice Disclosure and Securities Trading Policies, especially regarding transactions made by the Company itself, its management and other other people subject to the policies, with due caution.
3.Finally, the Board of Directors authorized the Company's Executive Board to perform all necessary acts and other additional acts for the implementation of the Program, and the Executive Board may negotiate the shares issued by the Company on the occasions it deems appropriate, subject to the terms and limits set forth in the Program and other limitations provided for in the proposal filed at the Company's headquarters and in the applicable rules, including RCVM 77/22.
There being no further matters to discuss, the meeting was concluded, and these minutes were written, read, passed, and signed by all the Board members present.
Jorge Marques de Toledo Camargo – Chairman
Marcos Marinho Lutz – Vice-Chairman
Ana Paula Vitali Janes Vescovi
Fabio Venturelli
Flávia Buarque de Almeida
Francisco de Sá Neto
José Mauricio Pereira Coelho
Marcelo Faria de Lima
Peter Paul Lorenço Estermann
Denize Sampaio Bicudo – Secretary of the Board of Directors
EXHIBIT I
INFORMATION ON APPROVAL OF TRADING OF OWN ISSUED SHARES
(as per Exhibit G to CVM Resolution No. 80, of March 29, 2022)
1. Justify in detail the purposes and
expected economic effects of the operation;
The
repurchased shares are intended to be used in the stock-based incentive plan,
approved by the Company’s General Shareholders’ Meeting, and may be held in
treasury and/or subsequently canceled or sold.
2. Inform the number of shares (i) in comprising the free float and (ii) already held in treasury;
The
Company has, on this date, (i) 1,090,253,154 (one billion, ninety million, two
hundred and fifty-three thousand, one hundred and fifty-four) registered common
shares outstanding, with no par value, and 24,471,457 (twenty-four million,
four hundred and seventy-one thousand, four hundred and fifty-seven) shares
held in treasury.
3. Inform the number of shares that
may be bought back or sold;
The
Company may buy back up to 25,000,000 shares issued by the Company,
representing, as of this date, 2.24% of the share capital, respecting the
maximum limit provided in art. 4 of CVM Resolution 77/22.
4. Describe the main characteristics
of the derivative instruments that the company may use in the future, if any;
In case of derivatives being used within the scope of this Program, the instrument to be used
will be swaps, in which the Company receives the price variation of its shares
traded on the stock exchange plus the proceeds (active end) and pays a
percentage of the CDI rate with or without a pre-fixed rate (passive end). The
contracts shall have a financial settlement and a maximum term of up to 12
months. The active end shall be backed by market-priced transactions carried
out on the stock exchange by the hired bank. The contracts will be negotiated
in the over-the-counter market and will be settled financially. The instruments
may provide for the need for giving collateral for net exposures above a
certain level.
5. Describe agreements or existing voting instructions between the company and the counterparty to the transactions, if any;
The
Company or the hired bank will carry out the transactions in the stock
exchange, at B3 S.A. – Brasil, Bolsa, Balcão (“B3”) and, therefore, it will not
be possible to specify in advance who the counterparties in the transactions
will be. In any case, the Company does not intend to enter into agreements or
voting guidelines with such counterparties.
6. In the event of transactions
carried out outside organized securities markets, inform: a. the maximum
(minimum) price at which the shares will be acquired (sold); and b. if
applicable, the reasons that justify the operation at prices more than 10% (ten
percent) higher, in the case of buyback, or more than 10% (ten percent)
lower, in the case of sale, than the average the stock quotes, weighted by
volume, in the 10 (ten) previous trading sessions;
Not
applicable, since the Company will carry out the transactions in the stock
exchange, at B3.
7. Inform, if any, the impacts that
the negotiation will have on the composition of the shareholding control or the
administrative structure of the company;
There
will be no significant impacts on the Company’s shareholding composition or its
administrative structure.
8. Identify the counterparties, if known, and, in the event that the counterparty is a party related to the company, as set out in the accounting rules that cover this matter, also provide information required by art. 9 of CVM Resolution No. 81, of March 29, 2022;
The
Program’s transactions will be carried out in the stock exchange, so it will
not be possible to specify the counterparties of each transaction in advance.
Additionally, the Company will observe the terms of the Material Notice
Disclosure and Securities Trading Policies, especially regarding transactions
made (i) by the Company itself, and (ii) by its management and other people
subject to the policies, with due precautions, including to prevent them from
being counterparties in the transactions.
9. Indicate the destination of the
funds earned, if applicable;
Not applicable, considering that, at this moment, the negotiation is limited to the buyback of shares and not the sale of the shares.
10. Indicate the maximum period for the
settlement of authorized operations;
The
maximum period for the acquisition of the shares is 12 (twelve) months,
starting on December 2, 2024, and ending on December 2, 2025 (including the
start and end dates).
11. Identify institutions that will act
as intermediaries, if any;
BTG PACTUAL CTVM S/A, CNPJ
43.815.158/0001-22;
ITAÚ CV S.A, CNPJ
61.194.353/0001-64;
J.P. MORGAN CORRETORA DE CÂMBIO
E VALORES MOBILIÁRIOS S/A, CNPJ 32.588.139/0001-94;
MERRILL
LYNCH S.A. CTVM, CNPJ 02.670.590/0001-95;
MORGAN
STANLEY CTVM S.A, CNPJ 04.323.351/0001-94; e
UBS BRASIL CORRETORA DE CÂMBIO
E TÍTULOS VALORES SA, 02.819.125/0001-73.
12. Specify the available funds to
be used, pursuant to art. 8, § 1, of CVM Resolution No. 77, of March 29, 2022;
According
to the financial statements for the quarter ended September 30, 2024, the
Company has R$ 6,267,568,512.86 in profit reserves considered as available
resources for the purposes of art. 8, § 1, of CVM Resolution 77/22.
13. Specify the reasons why the members
of the board of directors feel comfortable that the buyback of shares will
not affect the fulfillment of obligations assumed with creditors or the payment
of mandatory, fixed or minimum dividends.
The
members of the Board of Directors believe that the execution of the Program
will not affect Ultrapar’s ability to meet financial commitments, nor the
payment of dividends by the Company, also in accordance with the opinion of the
Company’s Executive Board. In the opinion of the management, the Company has a
comfortable liquidity position with a controlled level of leverage, which would
support the execution of the Program.
ULTRAPAR PARTICIPAÇÕES S.A.
Publicly Traded Company
CNPJ Nr. 33.256.439/0001-39
NIRE 35.300.109.724
ULTRAPAR’S SHARES BUYBACK PROGRAM
São Paulo, November 28, 2024 – Ultrapar Participações S.A. (“Company”), in compliance with CVM Resolution 44/21, 77/22 and 80/22, hereby informs that, the Board of Directors approved on this date Ultrapar’s Shares Buyback Program (“Program”).
The Program is limited to a maximum of 25,000,000 common shares and will last for 12 (twelve) months, starting from December 2, 2024. The shares bought back may be used in the Company’s stock-based incentive plan, held in treasury, and/or subsequently canceled or sold.
The Company will always buy back the shares in the stock exchange, in the cash market, observing the deadlines and limits set in the Program and other limitations provided for in the applicable regulations.
Additional information about the purposes, justifications, terms, and conditions applicable to the Program, in accordance with Exhibit G of CVM Resolution 80/22, can be found in Exhibit I below, on the Company’s Investor Relations page, in the CVM Empresas.NET System (www.cvm.gov.br), as well as on the website of B3 S.A. – Brasil, Bolsa Balcão (www.b3.com.br), as an attachment to the minutes of the meeting of the Board of Directors held on this date.
Rodrigo de Almeida Pizzinatto
Chief Financial and Investor Relations Officer
Ultrapar Participações S.A.
Exhibit I
INFORMATION ON APPROVAL OF TRADING OF OWN ISSUED SHARES
(as per Exhibit G to CVM Resolution No. 80, of March 29, 2022)
1.
Justify in detail the purposes and expected economic effects of the
operation;
The shares bought back are intended to be used in the stock-based incentive plan, approved by
the Company’s General Shareholders’ Meeting, and may be held in treasury and/or
subsequently canceled or sold.
2.
Inform the number of shares (i) comprising the free float and (ii) already held in
treasury;
The Company has,
on this date, (i) 1,090,253,154 (one billion, ninety million, two hundred and
fifty-three thousand, one hundred and fifty-four) registered common shares outstanding,
with no par value, and 24,471,457 (twenty-four million, four hundred and
seventy-one thousand, four hundred and fifty-seven) shares held in treasury.
3.
Inform the number of shares that may be bought back or sold;
The Company may
buy back up to 25,000,000 shares issued by the Company, representing, as of this
date, 2.24% of the share capital, respecting the maximum limit provided in art.
4 of CVM Resolution 77/22.
4.
Describe the main characteristics of the derivative instruments that the
company will use, if any;
In case of derivatives being used within the scope of this Program, the instrument to be used
will be swaps, in which the Company receives the price variation of its shares
traded on the stock exchange plus the proceeds (active end) and pays a
percentage of the CDI rate with or without a pre-fixed rate (passive end). The
contracts shall have a financial settlement and a maximum term of up to 12
months. The active end shall be backed by market-priced transactions carried
out on the stock exchange by the hired bank. The contracts will be negotiated
in the over-the-counter market and will be settled financially. The instruments
may provide for the need for giving collateral for net exposures above a
certain level.
5.
Describe, any agreements or voting guidelines existing between the
company and the counterparty of the transactions, if any;
The Company or
the hired bank will carry out the transactions in the stock exchange, at B3
S.A. – Brasil, Bolsa, Balcão (“B3”) and, therefore, it will not be possible to
specify in advance who the counterparties in the transactions will be. In any
case, the Company does not intend to enter into agreements or voting guidelines
with such counterparties.
6. In the event of transactions carried out outside organized securities
markets, inform: a. the maximum (minimum) price at which the shares will be
acquired (sold); and b. if applicable, the reasons that justify the operation
at prices more than 10% (ten percent) higher, in the case of buyback, or
more than 10% (ten percent) lower, in the case of sale, than the average the stock
quotes, weighted by volume, in the 10 (ten) previous trading sessions;
Not applicable,
since the Company will carry out the transactions in the stock exchange, at B3.
7. Inform, if any, the impacts that the negotiation will have on the
composition of the shareholding control or the administrative structure of the
company;
There will be no
significant impacts on the Company’s shareholding composition or its
administrative structure.
8.
Identify the counterparties, if known, and, in the event that the counterparty is a party related to the company, as set out in the accounting rules that cover this matter, also provide information required by art. 9 of CVM Resolution No. 81, of March 29, 2022;
The Program’s
transactions will be carried out in the stock exchange, so it will not be
possible to specify the counterparties of each transaction in advance.
Additionally, the Company will observe the terms of the Material Notice
Disclosure and Securities Trading Policies, especially regarding transactions
made (i) by the Company itself, and (ii) by its management and other people subject
to the policies, with due caution, including to prevent them from being
counterparties in the transactions.
9.
Indicate the destination of the funds earned, if applicable;
Not applicable,
considering that, at this moment, the negotiation is limited to the buyback of shares and not the sale of the shares.
10.
Indicate the maximum period for the settlement of authorized operations;
The maximum
period for the acquisition of the shares is 12 (twelve) months, starting on
December 2, 2024, and ending on December 2, 2025 (including the start and end
dates).
11.
Identify institutions that will act as intermediaries, if any;
BTG PACTUAL CTVM S/A, CNPJ
43.815.158/0001-22;
ITAÚ CV S.A, CNPJ 61.194.353/0001-64;
J.P. MORGAN CORRETORA DE CÂMBIO E
VALORES MOBILIÁRIOS S/A, CNPJ 32.588.139/0001-94;
MERRILL LYNCH
S.A. CTVM, CNPJ 02.670.590/0001-95;
MORGAN STANLEY
CTVM S.A, CNPJ 04.323.351/0001-94; e
UBS BRASIL CORRETORA DE CÂMBIO E TÍTULOS
VALORES SA, 02.819.125/0001-73.
12.
Specify the resources available funds to be used, pursuant to art. 8, § 1, of CVM
Resolution No. 77, of March 29, 2022;
According to the
financial statements for the quarter ended September 30, 2024, the Company has
R$ 6,267,568,512.86 in profit reserves considered as available resources for
the purposes of art. 8, § 1, of CVM Resolution 77/22.
13.
Specify the reasons why the members of the board of directors feel
comfortable that the buyback of shares will not affect the fulfillment of
obligations assumed with creditors or the payment of mandatory, fixed or
minimum dividends.
The members of
the Board of Directors believe that the execution of the Program will not
affect Ultrapar’s ability to meet financial commitments, nor the payment of
dividends by the Company, also in accordance with the opinion of the Company’s
Executive Board. In the opinion of the management, the Company has a
comfortable liquidity position with a controlled level of leverage, which would
support the execution of the Program.